The goal of the Tissue Culture Shared Service is to enhance the quality of laboratory research at the Arizona Cancer Center by providing specialized cell culture services to Cancer Center investigators. The objectives of the service include providing: 1. Cell lines for addressing cancer-related research questions; 2. Cost-effective quality control measures necessary for excellent science with in vitro cancer models; 3. Reagents for cell culture that are not commercially available or are more cost-effective when obtained through the service; 4. Consultative expertise in tissue culture; 5. Assistance to the genetically modified nice shared service in establishing knock-mice. More than 250 human tumor-derived cell lines have been established by the Tissue Culture Shared Service. Cancer Center investigators have used these in cytogenetic and molecular studies to identify genetic changes in cancer and in pharmacological studies to evaluate new chemotherapeutic agents. Cell lines from this bank also have been provided to the NCI and ATCC. This service provides cost effect mycoplasma screening of cell lines to encourage regular testing. This helps ensure that results obtained by Center investigators using in vitro models are not artifacts of mycoplasma infection. The service conducts quality assurance/quality control testing of fetal bovine serum lots. The effectiveness of different lots at supporting cell line growth relative to cost is assessed and large lot prices are then negotiated at a considerable savings to investigators. By maintaining embryonic stem cell culture for the Genetically Modified Mice Shared Service, it is anticipated that the expertise of the personnel in the Tissue Culture Shared Service will be key to the successful development of knock-out mouse models at the Arizona Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023074-22S2
Application #
6217328
Study Section
Project Start
1999-07-01
Project End
2000-06-30
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
22
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Arizona
Department
Type
DUNS #
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Kannaiyan, Radhamani; Mahadevan, Daruka (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 18:1249-1270
Berghout, Joanne; Li, Qike; Pouladi, Nima et al. (2018) Single subject transcriptome analysis to identify functionally signed gene set or pathway activity. Pac Symp Biocomput 23:400-411
Xie, Shuwei; Reinecke, James B; Farmer, Trey et al. (2018) Vesicular trafficking plays a role in centriole disengagement and duplication. Mol Biol Cell 29:2622-2631
Weinkauf, Craig C; Concha-Moore, Kirsten; Lindner, Jonathan R et al. (2018) Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging. J Vasc Surg 68:105S-113S
Song, Jin H; Singh, Neha; Luevano, Libia A et al. (2018) Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther 17:2710-2721
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26
Padilla-Rodriguez, Marco; Parker, Sara S; Adams, Deanna G et al. (2018) The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. Nat Commun 9:2980
Hupple, Clinton W; Morscher, Stefan; Burton, Neal C et al. (2018) A light-fluence-independent method for the quantitative analysis of dynamic contrast-enhanced multispectral optoacoustic tomography (DCE MSOT). Photoacoustics 10:54-64
Casillas, Andrea L; Toth, Rachel K; Sainz, Alva G et al. (2018) Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res 24:169-180
Nair, Uma S; Bell, Melanie L; Yuan, Nicole P et al. (2018) Associations Between Comorbid Health Conditions and Quit Outcomes Among Smokers Enrolled in a State Quitline, Arizona, 2011-2016. Public Health Rep 133:200-206

Showing the most recent 10 out of 1336 publications